Rein Therapeutics has reported preliminary blinded 12-week findings from the Phase II RENEW clinical study of its lead drug, LTI-03, for idiopathic pulmonary fibrosis (IPF).

The ongoing double-blind, placebo-controlled, randomised trial (NCT06968845) is designed to assess inhaled LTI-03 across two dose levels against placebo over 24 weeks in patients with IPF.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Its primary endpoint tracks safety and tolerability via treatment-emergent adverse event (TEAE) rates, while secondary measures evaluate forced vital capacity (FVC) changes, high-resolution computed tomography, and exploratory biomarkers.

The trial targets around 120 patients across Australia, Bulgaria, Germany, Poland, Romania, the UK, and the US.

An initial blinded review of 24 evaluable patients showed forced vital capacity (FVC) improvements from baseline in 33% of individuals, representing eight patients at week 12.

A further 46% of patients (11), exhibited a forced vital capacity reduction of 5.7% or less, while five participants recorded decreases exceeding 5.7%.

Regarding tolerability, investigators noted no serious TEAEs, with events being predominantly mild or moderate, including cough, and a study completion or continuation rate of 92%.

Rein Therapeutics president and CEO Brian Windsor said: “During the third quarter, we continued to make rapid progress in our Phase II RENEW trial for LTI-03 supported by strong enrolment and investigator enthusiasm.

“As we continue to enrol patients in the study, today’s blinded look at the data shows encouraging lung function trends and a favourable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need.

“We remain committed to advancing the study toward completion and look forward to reporting unblinded topline data in 2027.”

Financially, Rein reported a net loss of $5.5m for the third quarter ended 30 September 2026, slightly narrower than the $5.6m net loss recorded during the prior-year period.

Quarterly research and development expenditure rose by $2.7m year on year to $4.4m from $1.7m, driven by expanded activity in the RENEW trial.

General and administrative costs fell to $2.6m from $3.8m in the third quarter of 2025, primarily as a consequence of reduced spending on professional service fees.

The biopharmaceutical company held $36.5m in cash, cash equivalents, and marketable securities as of 30 September 2026, projected to fund clinical operations into the first quarter of 2028.

LTI-03 is a synthetic peptide derived from caveolin-1 biology and holds orphan drug designation (ODD) and fast track status from the US Food and Drug Administration (FDA).

Rein’s second pipeline asset, LTI-01, has concluded Phase Ib and Phase IIa evaluations in loculated pleural effusions, holding regulatory fast track and orphan drug statuses.